17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
4 May 2022 - TLV performs health economic assessments of medical technology products at the request of the Medical Technology Product ...
2 May 2022 - How should society handle new gene therapies for serious diseases, where the effect of the drugs is ...
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...